Delta-Fly Pharma, Inc. [4598.T]
TOKYO, Mar 26 (Pulse News Wire) – Delta-fly Pharma,inc. (4598.T) amended its previous clinical trial results involving DFP10,917 and VEN combination therapy.
In the initial report published on March 25, 2026, the efficacy rates were incorrectly stated as 50% for Phase 1 safety cohort and 53% for Phase 2 expansion cohort. The corrected figures now show 50% for Phase 1 and 53% for Phase 2, reflecting additional partial responses in the latter phase.
For the Phase 1 safety cohort, three out of six enrolled patients achieved complete remission (CR) or minor lymphocytic leukemia-free survival (MLFS). For the Phase 2 expansion cohort, nine out of seventeen patients demonstrated incomplete remission (CRi), MLFS, or partial response (PR).
This amendment underscores the ongoing evaluation process and highlights the importance of accurate reporting in clinical trials.
🟢 Confidence: High AI-translated content.